youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
SDGR:NASDAQ
Schrodinger Inc
$27.14
arrow_downward
-9.50%(-2.85) 1D
$27.14
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 30, 3:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SDGR...
Open
$29.00
High
$29.44
Low
$26.41
Mkt. cap
2.03B
Avg. vol.
2.56M
Volume
1.95M
52-wk high
$33.78
52-wk low
$10.95
EPS
-$0.74
Beta
1.62
Shares outstanding
65.64M
No. of employees
850
Open
$29.00
High
$29.44
Low
$26.41
Mkt. cap
2.03B
Avg. vol.
2.56M
Volume
1.95M
52-wk high
$33.78
52-wk low
$10.95
EPS
-$0.74
Beta
1.62
Shares outstanding
65.64M
No. of employees
850
News stories
From web sources and news partners
FourWeekMBA
·
1 hour ago
Apple Is Half the S&P 500’s Top Consumer Sales, Asymco Says
24/7 Wall St.
·
52 minutes ago
Bitcoin vs the S&P 500: $10,000 Invested 10 Years Ago, Which Won?
Traders Union
·
23 minutes ago
Michael A. Gayed: Weekly signal did not capture five-day panic in March 2023
BigGo Finance
·
12 hours ago
Nasdaq's 5.3% October Swoon: AI Capex Fears Meet a History of 24% Rebound Years
Profile
Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science.
Schrödinger's software is used by pharmaceutical companies, biotech, tech, chemicals, energy, aerospace firms, and academic researchers to simulate and model the behavior of molecules at the atomic level. This accelerates the design and develops new drugs and materials more efficiently, reducing the time and cost of bringing them to market.
Schrödinger's software tools include molecular dynamics simulations, free energy calculations, quantum mechanics calculations, and virtual screening tools. The company also offers consulting services and collaborates with partners in the industry to advance the field of computational chemistry and drug discovery. Wikipedia
About Schrodinger Inc
Analyst ratings
Based on 6 analysts giving stock ratings to SDGR in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for SDGR in the last 3 months.
Highest
Current $27.14
$32.00 (+17.91%)
Average
$26.20 (-3.46%)
Lowest
$17.00 (-37.36%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Kevin Caliendo UBS | Hold | Reiterated | $21.00 | -22.6% | 10/20/2026 |
Scott Schoenhaus KeyBanc | Buy | Maintained | $32.00 | +17.9% | 10/16/2026 |
Brendan Smith TD Cowen | Buy | Reiterated | $31.00 | +14.2% | 10/13/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $30.00 | +10.5% | 10/12/2026 |
Craig Hettenbach Morgan Stanley | Hold | Maintained | $17.00 | -37.4% | 09/15/2026 |
Sean Laaman Morgan Stanley | Hold | Reiterated | $17.00 | -37.4% | 08/12/2026 |
Michael Ryskin Bank of America Securities | Buy | Maintained | - | - | 08/06/2026 |
Matt Hewitt Craig-Hallum | Buy | Maintained | - | - | 07/08/2026 |
Michael Yee UBS | Hold | Reiterated | $13.00 | -52.1% | 03/17/2026 |
Next call in 3 days
Wed, Nov 4, 11:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.52
Revenue / Est. (USD)
- / 47.63M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 54.32M | 87.24M | 58.59M | 58.89M |
Cost of goods sold | 26.28M | 29.94M | 29.04M | 26.46M |
Cost of revenue | 26.28M | 29.94M | 29.04M | 26.46M |
Research and development expenses | 42.76M | 41.40M | 43.82M | 41.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 31.23M | 33.05M | 34.52M | 32.98M |
Operating expense | 73.99M | 74.45M | 78.34M | 73.98M |
Total operating expenses | 100.27M | 104.39M | 107.38M | 100.44M |
Operating income | -45.95M | -17.16M | -48.79M | -41.55M |
Other non operating income | 3.62M | 3.13M | 2.66M | 3.03M |
EBT including unusual items | -32.63M | 32.97M | -59.62M | 7.35M |
EBT excluding unusual items | -42.32M | -14.03M | -46.13M | -38.52M |
Income tax expense | 162.00K | 462.00K | 408.00K | 1.37M |
Effective tax rate | -0.50% | 1.40% | -0.68% | 18.67% |
Other operating expenses | - | - | - | - |
Net income | -32.80M | 32.51M | -60.03M | 5.98M |
Net profit margin | -60.37% | 37.27% | -102.46% | 10.15% |
Earnings per share | -0.57 | -0.18 | -0.62 | -0.42 |
Interest and investment income | - | - | - | - |
Interest expense | - | - | - | - |
Net interest expenses | - | - | - | - |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -44.48M | -15.72M | -47.32M | -40.06M |
Gain or loss from assets sale | - | - | 11.00K | -12.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events